

**P&T Motion History**  
**Diabetes – SGLT2 Inhibitors**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>canagliflozin dapagliflozin <b>empagliflozin</b></p>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Diabetes, I move that canagliflozin, empagliflozin and dapagliflozin are safe and efficacious for the treatment of their approved indications. Canagliflozin and dapagliflozin can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Therapeutic interchange is allowed only within each Diabetes subclass.</p> <p>Motion: Klingel 2<sup>nd</sup>: Figueroa</p>	<p>October 19, 2016</p>	<p>NA</p>	<p>No</p>	<p>Passed unanimous</p>